

# INTERNATIONAL JOURNAL OF INSTITUTIONAL PHARMACY AND LIFE SCIENCES

Pharmaceutical Sciences

Research Article.....!!!

Received: 17-11-2014; Revised: 25-12-2014; Accepted: 26-12-2014

## MICROBIOLOGICAL ASSAY AND *IN VITRO* CHARACTERISATION OF CEFACLOR MICROCAPSULES

Sujith Abraham\*, S. Mohan

Karpagam University, Pollachi Main Road, Eachanari Post, Coimbatore-641021, India.

### Keywords:

Cefaclor monohydrate,  
Sodium alginate,  
Microcapsule,  
Mucoadhesion

### For Correspondence:

**Sujith Abraham**

Karpagam University,

Pollachi Main Road,

Eachanari Post,

Coimbatore-641021, India

### E-mail:

[sujithabraham1@gmail.com](mailto:sujithabraham1@gmail.com)

### ABSTRACT

Microcapsules of mucoadhesive cefaclor monohydrate are prepared by ionotrophic gelation method using different concentration of sodium alginate, xanthan gum, guar gum and pectin in combination with 0.8% chitosan using cross linking agent calcium chloride. The microcapsules were evaluated for percentage yield, capsule size, entrapment efficiency, swelling index, mucoadhesion study by in vitro wash off test and scanning electron microscopy [SEM] analysis were investigated. Infrared spectroscopy studies (IR) confirmed the absence of any drug interaction with polymers. DSC analysis revealed that the drug was uniformly distributed in the microcapsule. The entrapment efficiency of all formulations was in the range of between 95% to 99%. The swelling index decreased with increase in sodium alginate concentration. The results of in vitro mucoadhesive showed that the microcapsules were remained adhered to mucus membrane for longer period of time. *In vitro* drug release studies were performed in simulated gastric fluid [SGF, pH 1.2] for 2 hrs and phosphate buffer [pH 6.5] for 10 hrs at  $37 \pm 2^\circ \text{C}$ . In vitro drug release followed. Drug release from the microcapsules was found slow releasing and following zero order kinetics, Korsmeyer & Peppas model. The diffusional exponent  $n$ , specified anomalous transport and non-fickian type and controlled by diffusion through swollen matrix. The above observations suggested that the cefaclor monohydrate can be developed as mucoadhesive drug delivery system with sodium alginate, xanthan gum, chitosan (7.5 : 1 : 0.8). Microbiological assay done using *Klebsiella Oxytoca* ATCC 49131, *Bacillus Subtilis* ATCC 6633, *Pseudomonas Aeruginosa* ATCC 9027, *Staphylococcus Aureus* ATCC 25923, *Escherichia coli* ATCC 10536, *Proteus Mirabilis* ATCC 29906.

## 1. INTRODUCTION

Cefaclor is a broad spectrum antibiotic belonging to the family of second generation cephalosporins. Cefaclor is well absorbed in the body, with a peak serum concentration occurring within 30-60 min, which is significantly reduced in the presence of food, with no change in the total amount of drug absorbed. Cefaclor is rapidly excreted in urine, with an approximate half – life of two hours. Because of its short half – life and large dose, cefaclor is considered a good candidate for sustained release dosage forms.

The purpose of present investigation is to develop mucoadhesive microcapsules with crosslinking agent like calcium chloride, and chitosan as mucoadhesive polymer with drug cefaclor monohydrate by ionotropic gelation method. The microcapsules maintain functionality under physiological conditions, can incorporate drug to deliver locally at high concentration ensuring that therapeutic levels are reached at the target site while reducing the side effects by keeping systemic concentration low. It will therefore be advantageous to have means for providing an intimate contact of the drug delivery system with the absorbing membranes. This can be achieved by coupling the bioadhesive characteristics to microcapsules and develop bioadhesive microcapsules. Bioadhesive microcapsules have advantages such as efficient absorption and enhanced bioavailability of drugs owing to high surface to volume ratio, a much more intimate contact to mucus layer and specific targeting of drugs to the absorption site.

## 2 MATERIALS AND METHODS

Cefaclor monohydrate was obtained as a gift sample from Sance laboratories, palai, Cochin. Sodium alginate was purchased from Yarrow Chem Products Mumbai, calcium chloride and xanthan gum, guar gum, and pectin were purchased from Nice chemical private limited, Kochi. Chitosan was purchased from Hi media laboratories Pvt limited, Mumbai.

### 2.1 Formulation of mucoadhesive microcapsules

The mucoadhesive alginate beads were prepared by ionotropic gelation method as per the composition shown in Table 1. An aqueous solution of various concentrations of sodium alginate, xanthan gum, guar gum and pectin is prepared with vigorous stirring to form a clear solution. Pectin, guar gum and xanthan gum is used in low concentration whereas high concentration will result in much higher viscosity of solution which was difficult to process for preparing the microcapsules. To this solution the drug Cefaclor monohydrate is added slowly and stirred continuously until a uniform dispersion is obtained. The dispersion is kept undisturbed for 30 minutes. The resultant bubble free, homogeneous dispersion is extruded into polyvalent ion solutions (200 ml) containing 0.8 % chitosan using a hypodermic syringe with 21 gauge needle

and stirred at 100rpm in magnetic stirrer. The microcapsules are cured in gelation medium for 15 mins and then collected by decantation technique and the product thus separated is washed with acetone for two times and dried at room temperature for 24 hours

**Table1: Composition of Cefaclor loaded microcapsules**

Formula	Cefaclor (%m/V)	Sod Alg(%m/V)	Chitosan (%m/V)	CaCl <sub>2</sub> (%m/V)	Xanthan gum(%m/V)	Guar gum(%m/V)	Pectin (%m/V)
FX1	5	1.5	0.8	4	0.20		
FX2	5	3.0	0.8	4	0.40		
FX3	5	4.5	0.8	4	0.60		
FX4	5	6.0	0.8	4	0.80		
FX5	5	7.5	0.8	4	1.0		
FX6	5	9.0	0.8	4	1.20		
FG7	5	1.5	0.8	4		0.20	
FG8	5	3.0	0.8	4		0.40	
FG9	5	4.5	0.8	4		0.60	
FG10	5	6.0	0.8	4		0.80	
FG11	5	7.5	0.8	4		1.0	
FG12	5	9.0	0.8	4		1.20	
FP13	5	1.5	0.8	4			0.20
FP14	5	3.0	0.8	4			0.40
FP15	5	4.5	0.8	4			0.60
FP16	5	6.0	0.8	4			0.80
FP17	5	7.5	0.8	4			1.0
FP18	5	9.0	0.8	4			1.20

## 2.2 Preformulation studies

### 2.2.1 FTIR studies

FT-IR spectra (Spectrum RX-1 Perkin-Elmer, German) for the drug and various physical mixtures are obtained in a FT-IR spectroscopy in the transmission mode with the wave number region 4000-500cm<sup>-1</sup>. KBr pellets are prepared by gently mixing 1mg sample powder with 100mg KBr.<sup>7</sup>

**2.2.2 DSC studies:** To detect any interaction between drug and polymer the DSC thermo grams of pure drug, polymers and physical mixture of drug and polymers were taken using DSC200 TA Instruments, USA. The samples are heated in sealed aluminium pan at a rate of 10 °/min over the temperature range of 5-400 °C under a nitrogen flow of 20 lb/cm.

## 3.EVALUATION OF MUCOADHESIVE MICROCAPSULE

### 3.1 Percentage yield

The percentage yield of microcapsules of various batches are calculated using the weight of final product after drying with respect to the initial total weight of the drug and polymer used for preparation of microcapsules and percent yields is calculated as per the formula mentioned below<sup>15-17</sup>

$$\text{Percentage yield} = \left( \frac{\text{Amount of dried microbeads}}{\text{Amount of drug} + \text{Amount of polymer}} \right) \times 100$$

### 3.2 Drug entrapment efficiency

Drug loaded microcapsules (100 mg) are crushed in glass mortar and pestle and suspended in 100 ml of phosphate buffer (pH 6.5) solution and kept for 24hr. It is stirred for 5 minute and filtered by whatmann filter paper. Drug content in the filtrate is determined by spectrophotometrically

Entrapment efficiency is calculated using the reported formula

$$\text{Entrapment efficiency} = \left( \frac{\text{Actual \% drug content}}{\text{Theoretical \% drug content}} \right) \times 100$$

$$\text{Actual drug content mg (\%)} = \left( \frac{\text{Absorbance of sample}}{\text{Absorbance of standard}} \right) \times 100$$

$$\text{Theoretical drug content mg (\%)} = \left( \frac{\text{Weight of drug in microbeads}}{\text{Microbeads sample weight}} \right) \times 100$$

### 3.3 Swelling studies by weight method:

A known weight (50mg) of microcapsules were placed in basket assembly of dissolution apparatus (USP XXIV) rotated at 500rpm in 500ml of pH 7.2 phosphate buffer solution maintained at  $37 \pm 0.5^\circ\text{C}$  and allowed to swell for the require period of time .The microcapsules were periodically removed, blotted with filter paper and their changes in weights were measured during the swelling until equilibrium was attained. Finally the weight of the swollen microspheres was recorded after a period of 6 hrs and the swelling ratio (SR) was calculated from the formula.

$$\text{Swelling index} = \frac{\text{mass of swollen microcapsules} - \text{mass of dried microcapsules}}{\text{mass of dried microcapsules}} \times 100$$

**3.4 *In vitro* dissolution studies:** An accurately weighed amount of drug loaded microcapsules equivalent to 16 mg are taken for *in vitro* dissolution studies. The microcapsules are filled into hard gelatin capsules and it is coated with Eudragit L 100 by dipping and drying method. The study is carried out in the USP Type II apparatus using 900 ml of buffer solution. The rotating speed of paddle is maintained at 50 rpm at  $37 \pm 1^\circ\text{C}$ . First two hour study is carried out in pH 1.2 and next ten hour study is carried out in phosphate buffer pH6.5. Samples are withdrawn every 15 mins for first one hour and then for every 30 mins. 10 ml of sample is withdrawn from buffer

medium, diluted with fresh medium and make upto 100ml. At the same time 10 ml of fresh medium was added to the dissolution medium to maintain the sink condition. 10 ml fresh medium and analyzed for cefaclor monohydrate content by the absorbance of the sample was determined by UV-Visible spectrophotometer at 264 nm.<sup>12-15</sup>

**3.5 Release kinetics** In order to understand the mechanism and kinetics of drug release, the drug release data of the in-vitro dissolution study are analyzed with various kinetic equations like zero-order, Higuchi and Peppas equation. Coefficient of correlation (r) values are calculated for the linear curves obtained by regression analysis of the above plots.

### **3.6 In vitro Wash - off test for mucoadhesion**

The mucoadhesive property of microcapsules were evaluated by an in vitro adhesion testing method known as wash – off method. Freshly excised piece of intestinal mucosa (2x2cm) from sheep intestine were mounted on to glass slides (3x1 inch) with cyanoacrylate glue. Two glass slides were connected with a suitable support about 50 microcapsules were spread on to each wet rinsed tissue specimen and immediately thereafter the support was hung onto the arm of a USP tablet disintegrating test machine. When disintegrating test machine was operated, the tissue specimen was given slowly, regular up and down movement in the test fluid (500ml pH7.2 buffer) maintained at 37 °C. At the end of 30 minutes, 1 hr and hourly intervals up to 8 hr, the number of microcapsules adhering to tissue were counted.

### **3.7 Scanning electron microscopic studies**

The morphology and surface structure of beads are observed using SEM photographs taken with SEM analyser. The beads are made conductive by sputtering thin coat of platinum under vacuum and then the images are recorded with at magnification of 25X.

### **3.8 X-ray diffraction (X-RD) studies**

Different samples were evaluated by X-ray powder diffraction. Diffraction patterns were obtained by using X-ray diffractometer (XRD-Shimadzu 7000) with a radius of 240mm. The Cu, K $\alpha$  radiation was Ni filtered. A system of diverging and receiving slits of 1° and 0.1mm respectively was used. The pattern was collected with 40 Kv of tube voltage and 30 mA of tube and scanned over the 2 $\theta$  range of 5-60°.

### **3.9. Microbiological study**

Sterilise the antibiotic assay medium by autoclave and prepare petriplates. Spread the test microorganism *Klebsiella oxytoca*, *Bacillus subtilis* on the surface of petriplate. Prepare cup or cavities on plate with sterile cork borer. Standard and test antibiotics are added to each labelled cavity. Transfer the plate to refrigerator at 4 degree for 1 to 2 hrs. Then incubate 35 degree for 48

hrs. Observe the zone of inhibition by antibiotic zone reader. Microbiological assay done using, *Klebsiella Oxytoca* ATCC 49131, *Bacillus Subtilis* ATCC 6633, *Pseudomonas Aeurugenosa* ATCC 9027, *Staphylococcus Aureus* ATCC 25923, *Escherichia coli* ATCC 10536, *Proteus Mirabilis* ATCC 29906

### **Bacteria**

Different bacterial strains were used as test strains: Microbiological assay done using, *Klebsiella Oxytoca* ATCC 49131, *Bacillus Subtilis* ATCC 6633, *Pseudomonas Aeurugenosa* ATCC 9027, *Staphylococcus Aureus* ATCC 25923, *Escherichia coli* ATCC 10536, *Proteus Mirabilis* ATCC 29906. All bacteria were obtained from the Microbiology Lab,


## **4.RESULTS AND DISCUSSION**

The objective of the present work is to develop different mucoadhesive formulations of cefaclor. Microcapsules of cefaclor were formulated by ionotropic gelation method. Eighteen formulations of microcapsules were prepared using different concentrations of sodium alginate, cross linking agent, xanthan gum, guar gum, and pectin and chitosan. The results observed are mentioned in the following sections.


### **4.1 Physical characterization**

In all formulations the alginate microcapsules were more or less spherical in shape and the exterior surfaces were rough. The spherical shape of the microcapsules in wet state was usually lost after drying especially for beads prepared with low concentration of sodium alginate and cross linking agent. With the increase of sodium alginate concentration the shape of the beads retained considerably.

### **4.2 Scanning electron microscopic studies**




**Figure 1: SEM micrograph of selected formulation FX-5**



**Figure 2 SEM micrograph of selected formulation FX-5**

#### Preformulation studies

#### 4.3 Size analysis of microcapsule



**Figure 3: Size analysis of prepared microcapsule formulation**

#### 4.4 In-vitro Wash - off test for mucoadhesion

The mucoadhesion is a phenomenon in which two materials, at least one of which is biological, are held together by means of interfacial force. The table shows the muco adhesion data of muco adhesive microcapsule carried out with everted rat intestinal mucosa in presence of phosphate buffer pH 7.2. The percentage of microcapsules retained on everted intestinal mucosa after 6 h in




set 1 formulation in the range of 60,55,65,71,68,67 for FX-1,FX-2,FX-3,FX-4,FX-5,FX-6 respectively and set 2 formulation in the range of 65,60,62,60,60,61 for FG-7,FG-8,FG-9,FG-10,FG-11,FG-12 respectively and for set 3 formulation in the range of 60,60,60,67,65 and 66 for FP-13,FP-14,FP-15,FP-16,FP-17,FP-18 respectively. The overall results suggest that concentration and type of mucoadhesive polymer doesn't show much more difference in the mucoadhesive property. Mucoadhesion was more with FX-4 (71%), FP-16 (67%) and FG-8(65%)

**Table 2: In-vitro Wash - off test for mucoadhesion of selected formulations**

Batches	Percentage of microcapsules adhering to tissue at different time interval (hr)					
	0	0.5	2.0	3.0	4.0	6.0
<b>FX-1</b>	50	88	80	64	60	60
<b>FX-2</b>	50	86	74	58	55	55
<b>FX-3</b>	50	96	85	77	65	65
<b>FX-4</b>	50	94	83	74	71	71
<b>FX-5</b>	50	96	88	79	68	68
<b>FX-6</b>	50	93	82	75	67	67


#### 4.5 FTIR studies

To check the compatibility of drug with various polymers, IR spectra of drugs, polymers and combination of the drug and polymers were taken. FTIR spectra of cefaclor monohydrate, sodium alginate, xanthan gum, pectin, guar gum and chitosan were recorded in KBr pellets and are presented in Figure 1. The IR spectral analysis of cefaclor monohydrate pure drug alone showed that principal peaks were observed at wave numbers  $3111.67\text{cm}^{-1}$ ,  $1551.14\text{cm}^{-1}$ . Further in the physical mixture of sodium alginate, xanthan gum, guar gum, pectin, chitosan and cefaclor monohydrate, the major peaks of were observed at  $3111.67\text{cm}^{-1}$ ,  $2940.58\text{cm}^{-1}$ ,  $1714.69\text{cm}^{-1}$ ,  $1551.14\text{cm}^{-1}$  and  $746.67\text{cm}^{-1}$  suggesting that there is no interaction between the polymers and drug used in the present study.



**Fig 4: FTIR spectra of pure drug cefaclor**







**Fig 5:FTIR spectra of cefaclor, xanthan gum, chitosan & sodium alginate**

#### 4.6 DSC studies

The DSC thermogram of pure drug and the different polymers were shown in the Figure 2. A sharp exothermic peak at about 201.59°C was observed for pure cefaclor. It was observed that the large exothermic peak of pure drug was a bit smaller and shifted to 201.94°C in physical mixture revealing its unchanged nature. This indicates that the drug has not undergone any chemical interaction with the polymer backbone.




**Figure 6: The DSC thermogram of pure drug cefaclor**




**Figure 7: The DSC thermogram of physical mixture (cefaclor, xanthangum, chitosan, & sodium alginate)**

## 4.7 X-ray diffraction (X-RD) studies



**Figure 8: XRD overlay spectra of pure drug cefaclor**



**Figure 9: XRD overlay spectra of pure drug cefaclor, xanthan gum, chitosan & sodium alginate)**

## 4.8 Evaluation of mucoadhesive microcapsules


### 4.8.1 Percentage yield

The percentage yield of microcapsules prepared by ionotropic gelation method were found to be between 83.45 % and 95.56 %. It was found that percentage yield of prepared microcapsules in calcium chloride was greater than xanthan gum, guar gum and pectin. A significant decrease in the production yield was observed with increase of alginate concentration. The probable reason behind this may be due to high viscosity of the solution which decreases its syringe ability resulting in blocking of needle and wastage of the drug polymer solution which ultimately decreased the production yield<sup>17</sup>.

The percentage yield of FX- formulations were in the range of  $89.46 \pm 0.78$  to  $95.56 \pm 0.31$

FG- formulations in the range of  $83.55 \pm 0.21$  to  $89.25 \pm 0.5$


FP formulations in the range of  $83.45 \pm 0.64$  to  $89.34 \pm 0.45$  the production yield was manageable with little loss of drug during the formulation stage



**Figure 10: Production yield of prepared microcapsules**

#### 4.8.2 Drug entrapment efficiency

The drug entrapment efficiency of all formulations was in the range between 95% and 99%. This is probably due to more firmness in the alginate-chitosan complex during gelation caused by increased ionic interactions between the carboxylate groups in the alginate and the protonated amine groups in the chitosan. The results of drug entrapment efficiencies were shown in graph .Pectin showed maximum drug entrapment efficiency then guar gum and xanthan gum.



**Figure 11: Microencapsulation efficiency of prepared microcapsules**

Drug entrapment efficiency of alginate beads increases with increase in concentration of polymers. The higher viscosity of the polymer solution at the highest polymer proportion would be expected to decrease the diffusion of the drug into the external phase which would result higher entrapment efficiency. This may be attributed to the greater availability of active binding sites in polymeric chains and consequently the greater degree of cross linking as the quantity of alginate increased.<sup>20</sup>

#### 4.8.3 Swelling studies

The swelling depends upon the polymer concentration, ionic strength as well as presence of water. The relative swelling of mucoadhesive microcapsules of set 1 formulations found in the range of 1.38, 1.42, 1.48, 1.16, 1.32 and 1.2 for FX-1, FX-2, FX-3, FX-4, FX-5, FX-6 respectively. For set 2 formulations found in the range of 1.09, 0.98, 1.06, 0.94, 0.98, and 1.02 for FG-7, FG-8, FG-9, FG-10, FG-11, FG-12 respectively, where as for set 3 formulations found in the range of 0.94, 1.06, 1.08, 1.02, 0.98 and 1.12 for FP-13, FP-14, FP-15, FP-16, FP-17, FP-18 respectively at the end of 6 hr. In all the formulations as the concentration of sodium alginate increases the relative swelling increases which further depend on the type of mucoadhesive polymers. The results clearly suggested swelling ratio depends upon concentration of polymer and type of mucoadhesive polymer used in the formulation. Swelling ratio shows direct relationship with sodium alginate concentration and increased with increasing concentration of sodium alginate. In all three sets, formulations having xanthan gum exhibited good swelling property compared to other mucoadhesive polymers.

#### 4.9 Stability test

The stability of formulation FX-5, FG-8 were tested at various conditions. The microcapsule FX-5 stored at  $4^{\circ} \pm 1^{\circ}\text{C}$ ,  $25^{\circ} \pm 2^{\circ}\text{C}$  ( $60 \pm 5\%$  RH) and  $37^{\circ} \pm 2^{\circ}\text{C}$  ( $65 \pm 5\%$  RH) for 90 days showed drug release of 97.03%, 97.63 % and 97.43% respectively. Initially, the same formulation showed 97.84 0.46% release of drug.


The microcapsule FG- 8 stored at  $4^{\circ} \pm 1^{\circ}\text{C}$ ,  $25^{\circ} \pm 2^{\circ}\text{C}$  ( $60 \pm 5\%$  RH) and  $37^{\circ} \pm 2^{\circ}\text{C}$  ( $65 \pm 5\%$  RH) for 90 days showed drug release of 96.12%, 96.30 % and 96.22% respectively. Initially, the same formulation showed 96.73 0.47 % release of drug. The result indicated that the selected formulation FX-5, FG-8 ensured stability during its shelf life.

#### 4.10 In-vitro dissolution studies

The results of *in-vitro* drug release studies from the mucoadhesive alginate microcapsules are shown in Figures FX, FG, FP and respectively.


The microcapsules did not show any drug release at pH 1.2 and it released the drug at pH 6.5. Above pH 6.0 Eudragit L 100 coating started to dissolve and exposed the microcapsules for drug release. So it protected the release of drug from the acidic medium to minimize the side effects.

FX set of formulations




**Figure 12: In vitro drug dissolution profiles of mucoadhesive microcapsules FX set formulation (xanthan gum)**

FG set of formulations



**Figure 13: In vitro drug dissolution profiles of mucoadhesive microcapsules FG set formulation (Guar gum)**

FP set of formulations



**Figure 14: In vitro drug dissolution profiles of mucoadhesive microcapsules FP set formulation (Pectin gum)**

#### 4.11 Release kinetics

Further the drug releases were subjected for mathematical treatment to check whether the release is following first order kinetics or zero order kinetics. The correlation coefficient values are shown in Table 3.

**Table 3: Release kinetics of prepared microcapsules**

	Zero order		First order		Higuchi		KorsemPeppas		Hixoncrowel	
	$R^2$	$Ko$	$R^2$	$K1$	$R^2$	KH	$R^2$	N	$R^2$	KHC
FX-1	0.926	7.582	0.702	-0.091	0.856	25.23	0.458	0.805	0.808	-0.218
FX-2	0.948	7.044	0.756	-0.098	0.957	25.78	0.444	0.777	0.883	-0.221
FX-3	0.949	6.393	0.987	-0.064	0.980	24.82	0.513	0.804	0.987	-0.170
FX-4	0.931	6.698	0.989	-0.073	0.987	26.35	0.551	0.857	0.985	-0.187
FX-5	0.985	7.294	0.788	-0.098	0.957	27.46	0.587	0.881	0.920	-0.223
FX-6	0.914	8.556	0.931	-0.136	0.996	30.90	0.468	0.876	0.984	-0.292
FG-7	0.891	0.139	0.221	-5.232	0.867	0.4208	0.391	0.908	0.979	-0.387
FG-8	0.980	7.057	0.816	-0.093	0.952	26.57	0.550	0.841	0.918	-0.214
FG-9	0.963	6.315	0.924	-0.064	0.939	23.82	0.491	0.765	0.952	-0.169
FG-10	0.951	5.806	0.965	-0.056	0.972	22.41	0.462	0.744	0.966	-0.149
FG-11	0.985	5.415	0.982	-0.041	0.968	20.51	0.612	0.846	0.990	-0.121
FG-12	0.989	5.513	0.970	-0.041	0.956	20.70	0.648	0.878	0.987	-0.123
FP-13	0.923	9.660	0.883	-0.161	0.995	32.77	0.444	0.900	0.975	-0.337
FP-14	0.791	8.521	0.966	-0.108	0.947	30.47	0.398	0.854	0.920	-0.259
FP-15	0.975	6.775	0.917	-0.071	0.968	25.79	0.643	0.933	0.963	-0.182
FP-16	0.843	6.374	0.965	-0.071	0.971	26.13	0.515	0.835	0.934	-0.180
FP-17	0.947	7.103	0.882	-0.117	0.983	27.63	0.486	0.802	0.958	-0.248
FP-18	0.980	6.060	0.968	-0.053	0.976	23.10	0.580	0.844	0.985	-0.149

The  $r$  values of zero order plots were between 0.981 to 0.986 and first order plot between 0.925 and 0.982. The  $r^2$  values indicate all these formulations followed zero order kinetics. The values of coefficient of correlation were found to be best fitted to Korsmeyerpeppas and Higuchi model. The  $R^2$  values are closer to one in zero order kinetics, so it follows zero order kinetics. The diffusional exponent,  $n$ , specifies the mechanism of release. For alginate beads, values of ' $n$ ' between 0.43 and 0.85 are an indication of both diffusion controlled drug release and swelling controlled drug release (anomalous transport or non-fickian diffusion). Values above 0.85 indicate case II transport which relate to polymer<sup>19-25</sup>




Figure 15:HIXON-CROWELL MODEL(FX-5 formulation)




Figure 16:korsmeyer-peppas model (fx-5)






Figure 17: ZERO ORDER MODEL FX-5




Figure 18: HIGUCHI MODEL (FX-5)





Figure 19: First order model FX-5

**Microbiological assay****Table 4: Microbiological assay of FX-5**

Formulations used	Zone of inhibition in mm	Zone of inhibition in mm	Zone of inhibition in mm	Zone of inhibition in mm	Zone of inhibition in mm	Zone of inhibition in mm
	<i>S Aureus</i>	<i>P Aurugenosa</i>	<i>B Subtilis</i>	<i>K Oxytoca</i>	<i>E coli</i>	<i>P Mirabilis</i>
Immediate release cefaclor 500 mg	28	32	26	24	17	31
Cefaclor microcapsule (FX-5) 500 mg	27	30	29	22	18	32
Cefaclor microcapsule (FX-5) 750 mg	29	33	31	26	21	35

**Fig 20: Microbiological assay of FX-5**

The sensitivity was more for *P mirabilis* > *P aurugenosa* > *B subtilis* > *S aureus* > *K oxytoca* > *E coli*.  
*E coli* is less sensitive because all enteric bacteria are less sensitive to cefaclor.

**Stability study****Table 5: Stability study of FX-5, FG-8, FP-17 microcapsules at 40<sup>0</sup> ± 2<sup>0</sup>C and 75 ± 5% RH)**

Sampling (after no of days)	Cefaclor content (%) Average ± SD			Physical appearance		
	FX-5	FG-8	FP-17	FX-5	FG-8	FP-17
0	97.84	96.73	97.5	Brown microcapsule	Dark yellow microcapsule	Off white microcapsule
15	97.72	96.69	97.45	NC	NC	NC
30	97.70	96.68	97.42	NC	NC	NC
60	97.67	96.66	97.38	NC	NC	NC
90	97.66	96.62	97.35	NC	NC	NC
120	97.62	96.58	97.32	NC	NC	NC
180	97.60	96.55	97.31	NC	NC	NC

NC-No change

**Table 6: Stability study of FX-5,FG-8,FP-17 microcapsules at  $25^{\circ} \pm 2^{\circ}\text{C}$  and  $60 \pm 5\% \text{ RH}$ )**

Sampling (after no of days)	Cefaclor content(%) Average $\pm$ SD			Physical appearance		
	FX-5	FG-8	FP-17	FX-5	FG-8	FP-17
0	97.84	96.73	97.5	Brown microcapsule	Dark yellow microcapsule	Off white microcapsule
15	97.71	96.71	97.48	NC	NC	NC
30	97.69	96.70	97.45	NC	NC	NC
60	97.68	96.68	97.43	NC	NC	NC
90	97.67	96.66	97.42	NC	NC	NC
120	97.64	96.64	97.40	NC	NC	NC
180	97.63	96.63	97.38	NC	NC	NC

NC-No change

The stability of formulation FX-5, FG-8, FP-17 were tested at various conditions.

The result indicated that the selected formulation FX-5,FG-8 ensured stability during its shelf life.

## 5. CONCLUSION

It was found that sodium alginate along with chitosan and xanthan gum substantially controlling the release of cefaclor monohydrate from the microcapsules. Results of the *in vitro* drug release indicated that the controlled drug release upto 12 hours. These studies demonstrated that cefaclor monohydrate can be encapsulated into microcapsules having sodium alginate, chitosan and xanthan gum backbone by ionic gelation technique having good yield, particle size, entrapment efficiency and *in vitro* drug release profile of microcapsules. The microcapsules also showed considerable swelling behavior. The prepared microcapsules showed controlled drug delivery behavior as can be inferred from the release kinetics data, as it follows zero order as well as Higuchi model which confirm its diffusion controlled release behavior although the Korsmeyer-Peppas plot shows anomalous transport suggests that the release is controlled by diffusion as well as by other factors like swelling of the microcapsules. These results demonstrate the efficiency of the new formulation FX-5 as a sustained antimicrobial oral dosage form. The prepared microcapsules showed sustained drug delivery in *in vivo* simulated study. The sensitivity was more for *P mirabilis* > *P aurigenosa* > *B subtilis* > *S aureus* > *K oxytoca* > *E coli*. *E coli* is less sensitive because all enteric bacteria are less sensitive to cefaclor.

## ACKNOWLEDGEMENT

The authors are thankful to Sance laboratories, Palai, Ernakulam for providing the gift sample of cefaclor monohydrate. We wish to thank the, Nirmala College of pharmacy Muvattupuzha, STIC, Cusat, Cochin, and Karpagam university coimbatore for providing facilities to carry out the present work.

## 6. REFERENCES

1. Vyas S.P and Roop K. Khar. Controlled drug delivery Concepts and Advances Vallabhprakashan 2002; 156-157.
2. John D. Smart. The basics and underlying mechanisms of mucoadhesion. Advanced Drug Delivery Reviews, 2005; 57: 1556– 1568.
3. Aulton ME (2002). Pharmaceutics: The science of dosage form design, 2nd ed., Churchill Livingston, New York, pp. 197-210.
4. B. K. A. Rasool and S. A. Fahmy: Development of coated beads for oral controlled delivery of cefaclor: *In vitro* evaluation, *ActaPharm.* 63 (2013) 31–44.
5. N. Pearnchob and R. Bodmeier, Dry polymer powder coating and comparison with conventionalliquid-based coatings for Eudragit RS, ethylcellulose and shellac, *Eur. J. Pharm. Biopharm.* 56(2003) 363–369; DOI: 10.1016/S0939-6411(03)00121-8.
6. R. Wise, The pharmacokinetics of the oral cephalosporins-a review, *Antimicrob. Agents Chemother.* 26 (1990) 13–20.
7. FláviaChivaCarvalho, Marcos Luciano Bruschi, Raul Cesar Evangelista, Maria Palmira DaflonGremiao. Mucoadhesive drug delivery systems. Braz J. pharm sci 2010;vol. 46, n. 1.
8. King B.A, Geelhoed Greactions associated with oral antibiotics in children:the role of cefaclor in serum siPaediatr., *Child HealthChohan Z.H.* Chem. Pharm. Bull., (Tokyo).80 (1991)
9. Chen X., ZhongDetermination of cefaclor in human plasma by asensitive and specific liquidChromatogr., *B Analyt.* 784, 17-24 (2003)
10. Anil K. Anal and Willem F. Stevens. Chitosan–alginate multilayer beads for controlled release of ampicillin. *Int. J. Pharm* 2005; 290 45–54.
11. Jill E. Shukla, Sachin J. Patel. Formulation and Evaluation of self micro emulsifying system of Candesartan Cilexetil. *Int. J. Pharm & Pharm sci.* 2010; 2(4); 749-756
12. A. Kakkar, Characterization of ibuprofen loaded microcapsules prepared by ionotropic gelation,*Indian J. Pharm. Sci.* 57 (1995) 56–60.
13. L. Xing, C. Dawei, X. Liping and Z. Rongqing, Oral colon-specific drug delivery for bee venompeptide: development of a coated calcium alginate gel beads-entrapped liposome, *J. Control. Release* 93 (2003) 293–300; DOI: 10.1016/j.jconrel.2003.08.019.
14. K. Yao, T. Peng and Y. He, Swelling kinetics and release characteristics of cross linked chitosan--polyether polymer network (sem: IPN) hydrogels, *J. Polym. Sci. A* 32 (1994) 1213–1219.

15. A. Sezer and J. Akbûga, Release characteristics of chitosan treated alginate beads ii. Sustained release of a low molecular weight drug from chitosan treated alginate beads, *J. Microencaps.* 16(1999) 687–696; DOI: 10.1080/026520499288636.
16. A. Kikuchi, M. Kawabuchi, A. Watanabe, M. Sugihara, Y. Sakurai and T. Okano, Effect of Ca-alginate gel dissolution on release of dextran with different molecular weights, *J. Control. Release* 58 (1999) 21–28; DOI: 10.1016/S0168-3659(98)00141-2.
17. *United States Pharmacopeia 30, National Formulary 25*, Vol 2, USP Convention, Rockville (MD)2007, pp. 277–284.
18. W. Korsmeyer, R. Gurny, E. Doelker, P. Buri and N. Peppas, Mechanisms of solute release from porous hydrophilic polymers, *Int. J. Pharm.* 15 (1983) 25–35; DOI: 10.1016/0378-5173(83)90064-9.
19. A. Bauer, M. Kirby, C. Sherris and M. Turck, Antibiotic susceptibility testing by standardized single disk method, *Am. J. Clin. Pathol.* 45 (1966) 493–496.
20. R. Barbhaiya, U. Shukla, C. Gleason, W. Shyu, R. Wilber and K. Pittman, Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration, *Antimicrob. Agents Chemother.* 34 (1990) 1204–1209.
21. S. Bajpai and R. Tankhiwale, Investigation of water uptake behavior and stability of calcium alginate/chitosan bipolymeric beads: Part-1, *React. Funct. Polym.* 66 (2006) 645–658; DOI: 10.1016/j.reactfunctpolym.2005.10.017.
22. D. Bhopatkar, A. Anal and W. Stevens, Iontropic alginate beads for controlled intestinal protein delivery: effect of chitosan and barium counter-ions on entrapment and release, *J. Microencaps.* 22 (2005) 91–100; DOI: 10.1080/02652040400026434.
23. L. Whithead, H. Collet and T. Fell, Amoxycillin release from a floating dosage form based on alginate, *Int. J. Pharm.* 210 (2000) 45–49; DOI: 10.1016/S0378-5173(00)00567-6.
24. K. Chourasia and K. Jain, Pharmaceutical approaches to colon targeted drug delivery system, *J. Pharm. Pharm. Sci.* 6 (2003) 33–66.
25. N. Pearnchob, A. Daskevsky and R. Bodmeir, Improvement in the disintegration of shellac-coated soft gelatin capsules in simulated intestinal fluid, *J. Control. Release* 94 (2004) 313–321; DOI: 10.1016/j.jconrel.2003.10.004.